Literature DB >> 16721295

Open-door laminoplasty for cervical myelopathy resulting from adjacent-segment disease in patients with previous anterior cervical decompression and fusion.

Morio Matsumoto1, Kenya Nojiri, Kazuhiro Chiba, Yoshiaki Toyama, Yasuyuki Fukui, Michihiro Kamata.   

Abstract

STUDY
DESIGN: This is a retrospective study of patients with cervical myelopathy resulting from adjacent-segment disease who were treated by open-door expansive laminoplasty.
OBJECTIVES: The purpose of this study was to evaluate the effectiveness of laminoplasty for cervical myelopathy resulting from adjacent-segment disease. SUMMARY OF BACKGROUND DATA: Adjacent-segment disease is one of the problems associated with anterior cervical decompression and fusion. However, the optimal surgical management strategy is still controversial.
METHODS: Thirty-one patients who underwent open-door expansive laminoplasty for cervical myelopathy resulting from adjacent-segment disease and age- and sex-matched 31 patients with myelopathy who underwent laminoplasty as the initial surgery were enrolled in the study. The pre- and postoperative Japanese Orthopedic Association scores (JOA scores) and the recovery rate were compared between the two groups.
RESULTS: The average JOA scores in the patients with adjacent-segment disease and the controls were 9.2 +/- 2.6 and 9.4 +/- 2.3 before the expansive laminoplasty and 11.9 +/- 2.8 and 13.3 +/- 1.7 at the follow-up examination, respectively; the average recovery rates in the two groups were 37.1 +/- 22.4% and 50.0 +/- 21.3%, respectively (P = 0.04). The mean number of segments covered by the high-intensity lesions on the T2-weighted magnetic resonance images was 1.87 and 0.9, respectively (P = 0.001).
CONCLUSIONS: Moderate neurologic recovery was obtained after open-door laminoplasty in patients with cervical myelopathy resulting from adjacent-segment disc disease, although the results were not as satisfactory as those in the control group. This may be attributed to the irreversible damage of the spinal cord caused by persistent compression at the adjacent segments.

Entities:  

Mesh:

Year:  2006        PMID: 16721295     DOI: 10.1097/01.brs.0000218632.82159.2b

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  Posterior surgery for cervical myelopathy: laminectomy, laminectomy with fusion, and laminoplasty.

Authors:  John M Rhee; Sushil Basra
Journal:  Asian Spine J       Date:  2008-12-31

2.  Different surgical approaches for the treatment of adjacent segment diseases after anterior cervical fusion: A retrospective study of 49 patients.

Authors:  Feng Wang; Peng Wang; De-Chao Miao; Wei Du; Yong Shen
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 3.  Ossification of the Posterior Longitudinal Ligament in Cervical Spine: Prevalence, Management, and Prognosis.

Authors:  Jau-Ching Wu; Yu-Chun Chen; Wen-Cheng Huang
Journal:  Neurospine       Date:  2018-03-28

4.  Artificial disc and vertebra system: a novel motion preservation device for cervical spinal disease after vertebral corpectomy.

Authors:  Jun Dong; Meng Lu; Teng Lu; Baobao Liang; Junkui Xu; Jie Qin; Xuan Cai; Sihua Huang; Dong Wang; Haopeng Li; Xijing He
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

5.  Primary cervical disc arthroplasty versus cervical disc arthroplasty adjacent to previous fusion: A retrospective study with 48 months of follow-up.

Authors:  Ting-Kui Wu; Yang Meng; Hao Liu; Ying Hong; Bei-Yu Wang; Xin Rong; Chen Ding; Hua Chen
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  Comparison between repeat anterior and posterior decompression and fusion in the treatment of two-level symptomatic adjacent segment disease after anterior cervical arthrodesis.

Authors:  Junming Cao; Can Qi; Yipeng Yang; Tao Lei; Linfeng Wang; Yong Shen
Journal:  J Orthop Surg Res       Date:  2020-08-08       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.